The U.S. Market for Cardiovascular Devices

Table of Contents

CHAPTER ONE: Executive Summary

• Background
• Cardiomyopathy/Congestive Heart Failure
  • Left Ventricular (LV) Failure
  • Right Ventricular (RV) Failure
  • Systolic Dysfunction
  • Diastolic Dysfunction
  • High Output Failure
• Arrhythmias
• Arteriosclerosis (Coronary Artery Disease)
• Heart Valve Disease
• Scope and Methodology
• Size and Growth of Market
• Competitive Picture
• Market Trends and Factors

CHAPTER tWO: Overview of Cardiovascular Disease

• Background
• Aneurysm
• Arrhythmias
• Athletic Heart Syndrome
• Cardiac Arrest
• Cardiac Tumors
• Cardiomyopathy
• Congenital Heart Disease
• Congestive Heart Failure
  • Types of Heart Failure
  • Left Ventricular (LV) Failure
  • Right Ventricular (RV) Failure
  • Systolic Dysfunction
  • Diastolic Dysfunction
  • High Output Failure
  • Theories of Heart Failure
  • Hemodynamic Response Theory
  • Neurohormonal Response Theory
  • Renal Response Theory
• Coronary Artery Disease
• Endocarditis
  • Infective Endocarditis
  • Subacute bacterial endocarditis (SBE)
  • Acute bacterial endocarditis (ABE)
  • Prosthetic valvular endocarditis
  • Right-sided endocarditis
  • Noninfective Endocarditis
• Hypertension/Hypotension
• Pericardial Disease
• Shock
  • Hypovolemic shock
  • Vasodilatory shock
  • Cardiogenic shock
• Valvular Heart Disease
• Vascular Disease

CHAPTER THREE: Demographics and Epidemiology

• Background
• Population Demographics
• Epidemiology and Pathology of Cardiovascular Diseases
• Cardiomyopathy/Congestive Heart Failure (CHF)
  • Types of Heart Failure
  • Left Ventricular (LV) Failure
  • Right Ventricular (RV) Failure
  • Systolic Dysfunction
  • Diastolic Dysfunction
  • High Output Failure
  • Theories of Congestive Heart Failure
  • Hemodynamic Response Theory
  • Neurohormonal Response Theory
  • Renal Response Theory
  • Conditions Leading to Congestive Heart Failure
• Arrhythmias
• Arteriosclerosis/Atherosclerosis
• Heart Valve Disease

CHAPTER FOUR: Therapeutic Cardiovascular Devices

• Overview
• Prosthetic Heart Valves
• Pacemakers
• Implantable Cardioverter-Defibrillators (ICDs)
• Ventricular Assist Devices (VADs)
• Total Artificial Heart Devices (TAHs)
• Coronary Artery Stents
• Cardiac Support Devices

CHAPTER FIVE: Market Analysis

• Market Size and Growth Overview
  • Cardiomyopathy/Congestive Heart Failure (CHF)
  • Arrhythmia
  • Arteriosclerosis
  • Heart Valve Diseases
• The 45+-Year-Old Market: A General View
  • Cardiomyopathy/Congestive Heart Failure
  • Arrhythmias
  • Arteriosclerosis
  • Valvular Heart Disease
• Competitive Outlook
• Market Trends

CHAPTER SIX: Company Profiles

• Overview
• Abbott Vascular Devices Division of Abbott Laboratories
• Abiomed, Inc.
• Acorn Cardiovascular, Inc.
• Arrow International
• Boston Scientific Corp.
• Cordis Corporation (A Johnson & Johnson Company)
• Guidant Corporation A Johnson & Johnson Company
• Medtronic, Inc.
  • Cardiac Rhythm Management (CRM)
  • Vascular
  • Cardiac Surgery
• MicroMed Technology, Inc.
• Myocor, Inc.
• St. Jude Medical
• Somanetics Corporation
• Somanetics Corporation
• Thoratec Corporation

Chapter Seven: Conclusions and Strategic Implications

• First Conclusion
• Implications:
• Second Conclusion
• Implications:
• Third Conclusion
• Implications:
• Fourth Conclusion
• Implications:
• Fifth Conclusion
• Implications:
• Sixth Conclusion
• Implications:
• Seventh Conclusion
• Implications:
• Eighth Conclusion
• Implications:
• Ninth Conclusion
• Implications:
• Tenth Conclusion
• Implications:
• Eleventh Conclusion
• Implications:
• Twelfth Conclusion
• Implications:
• Thirteenth Conclusion
• Implications:

APPENDIX A: Company Directory

APPENDIX B: Glossary

List of Exhibits

CHAPTER ONE: Executive Summary

• Table 1-1: Prevalence of Selected Cardiovascular Diseases in the United States for the Total Population and Those 45 Years of Age and Older 2004-2014
• Figure 1-1: Trending in United States Cardiovascular Disease Prevalence in the General Population and the 45+ Year Old Age Group 2004 - 2014
• Figure 1-2: Trending in U.S. Cases of Cardiomyopathy/Congestive Heart Failure 2004-2014
• Figure 1-3: Trending in U.S. Cases of Arrhythmia 2004-2014
• Figure 1-4: Trending in United States Cases of Arteriosclerosis (Coronary Artery Disease): 2004-2014
• Figure 1-5: Trending in U.S. Cases of Valvular Heart Disease 2004-2014
• Table 1-2: The Projected U.S. Total Available Market Potential of Therapeutic Devices for Cardiovascular Diseases by Type (Congestive Heart Failure, Arrhythmia, Arteriosclerosis and Heart Valve Disease) in the General Population and the Population Aged 45 Years and Older 2004-2014
• Figure 1-6: The Projected U.S. Total Available Market Potential of Therapeutic Devices for Cardiovascular Diseases in the General Population and the Population Aged 45 Years and Older 2004-2014
• Table 1-3: Key Competitors in the Therapeutic Cardiovascular Device Markets

CHAPTER tWO: Overview of Cardiovascular Disease

• Table 2-1: Benign and Malignant Cardiac Tumors
• Table 2-2: Common Contributors to Congestive Heart Failure

CHAPTER THREE: Demographics and Epidemiology

• Figure 3-1: Growth of the World?fs Elderly (60+ Years) Population 2001 - 2025
• Figure 3-2: Population Distribution of the United States by Age and Sex for 2000, 2005 and 2010
• Figure 3-3: The Growing United States Population: 2004-2014
• Figure 3-4: Projected Increasing Median Age of the United States Population: 2004-2014
• Figure 3-5: Projected Increasing Mean Age of the United States Population: 2004-2014
• Table 3-1: Prevalence of Selected Cardiovascular Diseases (CVD) in the United States for the Total Population and Those 45 Years of Age and Older: 2004 - 2014
• Figure 3-6: Trending in United States Selected Cardiovascular Disease (CVD) Cases in the General Population and the 45+ Year Old Age Group: 2004 - 2014
• Table 3-2: Prevalence Statistics for Different Types of Cardiomyopathy in the United States
• Table 3-3: Common Contributors to Congestive Heart Failure
• Table 3-7: Trending in the Prevalence of Cardiomyopathy/Congestive Heart Failure in the United States (Total Population and Those Aged 45 Year and Older) 2004-2014
• Table 3-4: Types of Arrhythmias
• Table 3-5: Prevalence Statistics for Types of Arrhythmias in the United States (22 types)
• Table 3-8: Trending in the Prevalence of Arrhythmia in the United States (Total Population and Those Aged 45 Year and Older) 2004-2014
• Table 3-9: Trending in the Prevalence of Arteriosclerosis (CAD) in the United States (Total Population and Those Aged 45 Year and Older) 2004-2014
• Table 3-10: Trending in the Prevalence of Heart Valve Disease in the United States (Total Population and Those Aged 45 Year and Older) 2004-2014

CHAPTER FOUR: Therapeutic Cardiovascular Devices

• Table 4-1: Key Providers of Prosthetic Heart Valves
• Table 4-2: Key Providers of Pacemakers
• Table 4-3: Key Providers of ICDs
• Table 4-4: Key Providers of VADs
• Table 4-5: Key Providers of TAHs
• Table 4-6: Candidate Drugs for Drug-Eluting Stents
• Table 4-7: Companies Active in Drug-Eluting Stent Commercialization
• Table 4-8: Key Providers of Cardiac Support Devices

CHAPTER FIVE: Market Analysis

• Table 4-1: The Projected U.S. Total Available Market Potential for Therapeutic Devices by Condition (Arteriosclerosis, Cardiomyopathy/Congestive Heart Failure, Arrhythmia and Heart Valve Disease) 2004-2014
• Figure 4-1: Trending in the Projected U.S. Total Available Market Potential Therapeutic Devices by Condition (Arteriosclerosis, Cardiomyopathy/Congestive Heart Failure, Arrhythmia and Heart Valve Disease) 2004-2014
• Figure 4-2: Trending in the Projected U.S. Total Available Market Potential for Therapeutic Cardiovascular Devices Used for the Treatment of Cardiomyopathy/Congestive Heart Failure 2004-2014
• Figure 4-3: Trending in the Projected U.S. Total Available Market Potential for Therapeutic Cardiovascular Devices in the Treatment of Arrhythmias 2004-2014
• Figure 4-4: Trending in the Projected U.S. Total Available Market Potential for the Therapeutic Cardiovascular Devices in the Treatment of Arteriosclerosis 2004-2014
• Figure 4-5: Trending in the Projected U.S. Total Available Market Potential for Therapeutic Cardiovascular Devices in the Treatment of Heart Valve Diseases 2004-2014
• Table 4-2: The Projected U.S. Total Available Market Potential for Therapeutic Devices in the 45+ Year Old Age Group by Condition (Arteriosclerosis, Cardiomyopathy/Congestive Heart Failure, Arrhythmia, and Heart Valve Disease) 2004-2014
• Figure 4-6: Trending in the Projected U.S. Total Available Market Potential for Therapeutic Devices in the 45+ Year Old Age Group by Condition (Arteriosclerosis, Cardiomyopathy/Congestive Heart Failure, Arrhythmia, and Heart Valve Disease) 2004-2014
• Figure 4-7: Trending in the Projected U.S. Total Available Market Potential for Therapeutic Cardiovascular Devices in the Treatment of Cardiomyopathy/Congestive Heart Failure in the 45+-Year-Old Population 2004-2014
• Figure 4-8: Trending in the Projected U.S. Total Available Market Potential for Therapeutic Cardiovascular Devices in the Treatment of Arrhythmias in the 45+-Year-Old Population 2004-2014
• Figure 4-9: Trending in the Projected U.S. Total Available Market Potential for Therapeutic Cardiovascular Devices in the Treatment of Arteriosclerosis in the 45+-Year-Old Population 2004-2014
• Figure 4-10: Trending in the Projected U.S. Total Available Market Potential for Therapeutic Cardiovascular Devices in the Treatment of Heart Valve Disease in the 45+-Year-Old Population 2004-2014